#

Eli Lilly

: 92
Pharmaceutical giant Eli Lilly sagged 1.1% in trading on March 17. Photo: Jonathan Weiss/Shutterstock
News·
Eli Lilly received a rare "sell" recommendation from analysts. Shares fell by 6%
Pharma is the most defensive sector amid conflict in the Middle East - UBS/Photo: shutterstock.com/Jonathan Weiss
News·
'Most defensive sector': UBS names stocks that can 'safely survive war'
According to three investment banks Eli Lilly could emerge as the leader in the weight loss drug race / Photo: Tada Image / Shutterstock.com
News·
Three investment banks named Eli Lilly as the leader in the weight loss drug race
The failure of Novo Nordisks experimental drug trial collapsed the companys shares and pulled Danish markets / Photo: Tada Images / Shutterstock
News·
Novo's failure to test a weight loss drug has sparked a sell-off in the Danish market
A Motley Fool analyst says Viking is the under-the-radar GLP-1 contender that growth hunters cant ignore / Photo: Facebook / Nasdaq
Small Caps·
Motley Fool calls Viking the GLP‑1 drugmaker growth-hunting investors 'can't ignore'
Novo Nordisk shares fell after Him&Hers announced the launch of its weight loss pill/ Photo: x.com/novonordisk
News·
Novo Nordisk and Eli Lilly shares plummet: the weight-loss pill will have a $49 copy
JOLTS data for December, postponed due to the shutdown, will be released today to clarify the dynamics of labor demand / Photo: Unsplash/sol
News·
Morning in New York: statistics and corporate news will determine the trading vector
Eli Lilly forecasts revenue growth of 23-27% in 2026 / Photo: Tada Images/Shutterstock.com
News·
Eli Lilly predicted revenue growth of 27% in 2026. Why is it better than Novo Nordisk?
Novos revenue could fall 5-13% in 2026/ Photo: Kittyfly/ Shutterstock.com
News·
Novo Nordisk warned of a drop in revenue in 2026. Quotes collapsed by 15%
Alphabet, Googles parent company, will release its quarterly report this week / Photo: Shutterstock.com
News·
Google and Amazon earnings, US employment: what investors need to know this week
A generic price war could drop the cost of semaglutide in some countries to $15 for a monthly course / Photo: charlesdeluvio / Unsplash.com
Review·
Substance-for-money exchange: $32 billion semaglutide market enters patent collapse phase
Half of weight loss drug users dream of going to the gym, Stifel has found / Photo: Jonathan Weiss / Shutterstock.com
News·
Stifel expects fitness chain's stock to rise 30%. How will a diet pill help them?
Load more